NasdaqCM - Delayed Quote USD

Veru Inc. (VERU)

1.2700 +0.0600 (+4.96%)
At close: April 26 at 4:00 PM EDT
1.2793 +0.01 (+0.73%)
After hours: April 26 at 7:09 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
15,929.8900
16,296.9580
39,354.3520
61,259.5280
42,592.0600
Cost of Revenue
7,915.5650
8,731.0300
8,762.9640
13,332.3050
11,805.2020
Gross Profit
8,014.3250
7,565.9280
30,591.3880
47,927.2230
30,786.8580
Operating Expense
74,902.5170
103,171.7670
114,079.5460
53,364.7240
31,433.5520
Operating Income
-66,888.1920
-95,605.8390
-83,488.1580
-5,437.5010
-646.6940
Net Non Operating Interest Income Expense
-1,718.7680
-2,427.0410
-4,368.7980
-4,886.0540
-4,621.4220
Other Income Expense
6,427.0280
5,360.3940
4,052.7350
14,588.7910
-14,783.8600
Pretax Income
-62,179.9320
-92,672.4860
-83,804.2210
4,265.2360
-20,051.9760
Tax Provision
476.0450
480.2060
236.3970
-3,129.1380
-1,078.4410
Net Income Common Stockholders
-62,655.9770
-93,152.6920
-84,040.6180
7,394.3740
-18,973.5350
Diluted NI Available to Com Stockholders
-62,655.9770
-93,152.6920
-84,040.6180
7,394.3740
-18,973.5350
Basic EPS
-0.70
-1.10
-1.05
0.10
-0.28
Diluted EPS
-0.70
-1.10
-1.05
0.09
-0.28
Basic Average Shares
89,984.2010
84,973.3820
80,122.5260
76,272.8530
66,753.4500
Diluted Average Shares
89,984.2010
84,973.3820
80,122.5260
83,802.4200
66,753.4500
Total Operating Income as Reported
-64,146.1970
-93,782.2160
-83,488.1580
12,972.6570
-14,746.6940
Total Expenses
82,818.0820
111,902.7970
122,842.5100
66,697.0290
43,238.7540
Net Income from Continuing & Discontinued Operation
-62,655.9770
-93,152.6920
-84,040.6180
7,394.3740
-18,973.5350
Normalized Income
-67,390.5236
-96,934.1242
-86,850.6480
-3,366.6713
-5,108.0130
Interest Expense
1,718.7680
2,427.0410
4,368.7980
4,851.7530
4,547.8130
Net Interest Income
-1,718.7680
-2,427.0410
-4,368.7980
-4,886.0540
-4,621.4220
EBIT
-60,461.1640
-90,245.4450
-79,435.4230
9,116.9890
-15,504.1630
EBITDA
-60,182.3790
-89,975.5710
-79,225.8280
9,328.3830
-15,041.4220
Reconciled Cost of Revenue
7,915.5650
8,731.0300
8,762.9640
13,332.3050
11,805.2020
Reconciled Depreciation
278.7850
269.8740
209.5950
211.3940
462.7410
Net Income from Continuing Operation Net Minority Interest
-62,655.9770
-93,152.6920
-84,040.6180
7,394.3740
-18,973.5350
Total Unusual Items Excluding Goodwill
5,993.0970
4,786.6230
3,557.0000
14,741.1580
-14,657.0000
Total Unusual Items
5,993.0970
4,786.6230
3,557.0000
14,741.1580
-14,657.0000
Normalized EBITDA
-66,175.4760
-94,762.1940
-82,782.8280
-5,412.7750
-384.4220
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0001
Tax Effect of Unusual Items
1,258.5504
1,005.1908
746.9700
3,980.1127
-791.4780
9/30/2020 - 2/11/1999

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NKGN NKGen Biotech, Inc.
1.6100
-18.69%
 
JAGX Jaguar Health, Inc.
0.1800
+5.88%
 
CADL Candel Therapeutics, Inc.
6.39
-0.62%
 
ANVS Annovis Bio, Inc.
18.01
+32.43%
 
OCGN Ocugen, Inc.
1.2800
+8.47%
 
EYEN Eyenovia, Inc.
0.6282
-11.68%
 
TVGN Tevogen Bio Holdings Inc.
1.0000
+17.65%
 
GLSI Greenwich LifeSciences, Inc.
13.12
+6.32%
 
VNDA Vanda Pharmaceuticals Inc.
4.6200
+3.12%
 
SLS SELLAS Life Sciences Group, Inc.
1.4600
-3.95%